In November of 2023, the FDA quietly moved BPC-157 to its Category 2 list of bulk drug substances. That bureaucratic act, which most people never heard about, effectively pushed one of the most useful healing peptides ever discovered out of the legal compounding pharmacy market in the United States and into the gray-market shadow economy.
That decision wasn’t an isolated incident. It was the leading edge of a broader regulatory push that, over the last two years, has pulled GHK-Cu, AOD-9604, Selank, Semax, MOTS-c, and a dozen other peptides off the compounding lists. The FDA has signaled that more are coming.
I want to talk plainly about what’s actually happening here, who benefits, who pays the cost, and what the harm-reduction case looks like when you take the moral panic out of the conversation.
What actually happened
Section 503A of the Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to prepare drugs from bulk substances for individual patients with a prescription. To be eligible for compounding, a substance needs to either be a component of an FDA-approved drug, be on the official USP/NF monograph list, or appear on the FDA’s “503A Bulks List.” Anything not on those lists is off-limits.
For years, BPC-157 sat in a kind of regulatory limbo. It wasn’t approved as a drug. It wasn’t on the 503A list. But compounding pharmacies were preparing it anyway, often citing the historical “research use” exemption and the absence of explicit prohibition. The FDA didn’t push back hard. Patients got access. Pharmacies operated in a tolerated gray zone.
In 2023 the FDA’s Pharmacy Compounding Advisory Committee took up the question formally and recommended that BPC-157 be classified Category 2 — meaning it should not be used in compounded preparations. The classification has been justified on grounds of “safety concerns,” specifically referencing the lack of FDA-approved human clinical trials.
The “safety concern” sleight of hand
The argument that BPC-157 has “safety concerns” deserves a careful look. The peptide has been studied in animal models since the early 1990s. There are thousands of academic papers documenting its mechanism, its pharmacokinetics, and its therapeutic effects on gastric ulcers, tendon injury, ligament repair, and inflammatory bowel conditions. The toxicology profile in animal studies is striking — even at doses orders of magnitude above the human therapeutic range, no consistent toxicity has been documented. There are no death reports linked to BPC-157 in the medical literature. There are no recurrent serious adverse event signals from the off-label user community.
Contrast that with the prescription pharmaceuticals the FDA approves every year. Statins, SSRIs, GLP-1 agonists, biologics — all come to market with documented adverse event profiles that include hospitalizations and deaths. The FDA approves them anyway, because the benefit-risk calculation favors approval. That’s the right framework.
What’s strange about the BPC-157 decision is that the safety profile of this peptide, by any honest reading, is cleaner than most over-the-counter medications. The supposed “safety concern” isn’t about real harm. It’s about the absence of formal human trials.
And that’s where the conversation gets uncomfortable. Because the only entity that can fund the kind of trials the FDA wants is a pharmaceutical company. And no pharmaceutical company is going to invest tens of millions of dollars into trials for a compound that cannot be patented — BPC-157 is a fragment of a naturally occurring protein, identified by Croatian researchers thirty years ago, in the public domain. There is no commercial pathway that justifies the trial cost. So the trials will never happen. So the peptide will never meet the FDA’s bar. So the FDA will continue to call it “experimental” forever.
The result: a compound with an exceptionally clean safety profile gets pushed off the legal market, and the people who were quietly using it for tendonitis, post-surgical recovery, and gut healing now have to choose between giving up the tool or buying it from offshore vendors with no quality control. Which outcome actually maximizes safety?
Who actually benefits from this
Whenever a regulatory move doesn’t match the stated rationale, follow the money.
Pharmaceutical companies. Several biotech firms have developed proprietary peptide analogs that compete with the public-domain peptides. When the public-domain version is pushed out of the legal market, the patented alternative becomes the only legal option. The price differential between, say, a compounded peptide at $40 per month and a patent-protected branded version at $1,200 per month is the entire business case.
Insurance and PBMs. Insurance companies don’t pay for compounded peptides. They do pay (selectively) for FDA-approved drugs. The system is designed to channel patient demand toward products with stable reimbursement codes, even when the off-label compounded option is cheaper and equally effective.
The FDA itself. Bureaucratic incentive structures favor adding to the regulatory perimeter. A more crowded list of categorically prohibited substances creates more enforcement work, justifies larger budgets, and gives the agency more leverage in its conversations with the compounding industry.
None of these incentives have anything to do with patient safety. They have to do with capture. The compounding industry’s BPC-157 problem isn’t that the peptide is dangerous — it’s that the existing players cannot capture the revenue stream that a regulated, patented version would generate.
The harm-reduction case
Here’s the practical reality. The FDA’s move pushed thousands of users off the legal compounding market. Some of those users gave up the peptide. The rest didn’t. They went to the gray market — research-chemical sites, international vendors, lyophilized vials of unknown provenance. The peptide is just as available as it was before. The only thing that changed is the chain of custody.
Compare this to harm-reduction frameworks in other areas of medicine. We don’t outlaw needle exchanges because we think shooting heroin is safe; we run them because we recognize that prohibition shifts behavior toward more dangerous patterns. Same logic applies here. If users are going to use a compound, the public-health-optimal policy is to keep that use as safe and clean as possible. That means regulated compounding pharmacies with third-party-tested raw material, not a Telegram channel selling lyophilized peptides from a warehouse in Eastern Europe.
The FDA’s decision did not reduce BPC-157 use. It just moved that use into a worse environment.
What “medical freedom” actually means
I’m not a libertarian for its own sake. I think regulation has a role. The FDA’s core mandate — keeping unsafe drugs out of the market — is one of the most important consumer protections we have. The drugs that killed people in the early 20th century, the contaminated insulin scandals, the thalidomide tragedy — all of those are exactly the cases where the FDA’s authority was justified and well-applied.
But the FDA has drifted far from that core mandate. Today it operates as the gatekeeper for whether competent adults can access compounds that have been used safely for decades, on the basis of a procedural standard (FDA-approved trials) that the structural economics of the underlying compound make impossible to satisfy. That’s not consumer protection. That’s gatekeeping for its own sake.
The medical freedom case isn’t “people should be able to take whatever they want with no oversight.” It’s “competent adults, in consultation with informed clinicians, should be able to access compounds with established safety profiles, even when those compounds don’t fit neatly into the pharmaceutical industry’s commercial model.”
That principle would apply to BPC-157. It would apply to most of the research peptides currently being pushed off the compounding lists. It would apply to a lot of other things the FDA currently restricts on grounds that have nothing to do with actual safety and everything to do with the regulatory bureaucracy’s own incentives.
What you can actually do
If you’ve been using BPC-157, GHK-Cu, or any of the other peptides that have been pushed off the legal market, your options narrowed but they did not disappear. Here’s the harm-reduction perspective.
Find an international source with documented quality control. Several jurisdictions outside the U.S. still allow compounding pharmacies to prepare these peptides. Australian and Thai compounding pharmacies are two examples. If you have a legitimate medical reason and you’re willing to navigate international shipping, this is the cleanest option.
Use a research-grade vendor with third-party COAs. If you must use the gray market, demand certificates of analysis from an independent lab for every batch. Several vendors comply with this. The ones that don’t, walk away.
Reconstitute carefully and store properly. Lyophilized peptides reconstituted with bacteriostatic water and refrigerated have stability profiles measured in weeks. Mishandled product is where actual harm comes from.
Get bloodwork before and during use. The single most important harm-reduction measure for any off-label compound is objective monitoring. Pre-use bloodwork, periodic monitoring, and a willingness to abort if something goes sideways.
Engage your political voice. The FDA’s Pharmacy Compounding Advisory Committee takes public comment. So do the relevant Congressional oversight committees. The peptide user community has been politically inert for too long. The cannabis legalization movement is a model for how a marginalized but legitimate user community can move public policy over a 20-year horizon.
The broader pattern
The FDA peptide crackdown is one piece of a larger pattern that includes the agency’s approach to nicotine harm reduction, kratom, ibogaine, and a half-dozen other compounds where the actual safety data is much more favorable than the regulatory posture would suggest. The agency consistently applies a precautionary standard to non-pharmaceutical compounds that it does not apply to its own approved drug pipeline.
The same FDA that warns about the “experimental” status of BPC-157 has approved more than thirty new drugs in 2024 with documented adverse event profiles including cardiovascular complications, hepatic injury, and serious psychiatric reactions. The standard isn’t “is this compound safe?” It’s “is this compound moving through the pharmaceutical approval pipeline?” If yes, the FDA is supportive. If no, the FDA is hostile. That’s not consumer protection. That’s institutional capture.
The cost of this pattern is real. People who could have benefitted from a clean, low-cost, well-characterized peptide will instead never use one, or will use one of lower quality from a worse source. People will hold onto musculoskeletal injuries longer than they need to. People will resort to surgeries that could have been avoided. The agency that exists to protect public health is, in this specific category, actively reducing it.
Where I land
I will continue to use BPC-157 and the other peptides in my personal toolkit. I will source them carefully. I will share my protocols transparently with my readers because that transparency is itself a harm-reduction measure — better that people have access to honest dosing and safety information than that they fumble in the dark.
I will continue to recommend that anyone using these compounds get bloodwork, work with a knowledgeable clinician where possible, and approach the entire space with respect rather than recklessness.
And I will continue to call out the FDA’s drift from its core mandate when I see it. Because the patients who get hurt by this regulatory pattern are not the ones who can afford a thousand-dollar-a-month branded alternative. They’re the average people trying to recover from an injury or manage a chronic inflammatory condition on a budget. The system, as currently structured, treats them as collateral damage. They deserve better.
Bottom line
The FDA’s peptide crackdown is not what it claims to be. It is not about consumer safety, because the compounds in question have safety profiles that compare favorably to the agency’s own approved products. It is about regulatory capture, the protection of incumbent pharmaceutical interests, and the structural inability of public-domain compounds to satisfy a procedural standard that the system makes economically impossible to meet.
Competent adults should be able to access well-characterized compounds with established safety profiles, in consultation with informed clinicians, regardless of whether those compounds fit the pharmaceutical industry’s commercial model. That’s the position. The actions of the FDA in the peptide space over the last three years are not consistent with that principle, and they should be challenged on those grounds.